Loading…
Scilex Holding Company is projected to rise to $10.17 by 2027, a +11% move from its current price of $9.20. SCLX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $8.58 | $9.21 | $9.88 | +0.07% |
| Jul 13 | $8.34 | $9.21 | $10.18 | +0.15% |
| Jul 14 | $8.16 | $9.22 | $10.42 | +0.22% |
| Jul 15 | $8.01 | $9.23 | $10.63 | +0.29% |
| Jul 16 | $7.88 | $9.23 | $10.81 | +0.36% |
| Jul 17 | $7.77 | $9.24 | $10.99 | +0.44% |
| Jul 18 | $7.67 | $9.25 | $11.15 | +0.51% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $7.67 | $9.25 | $11.15 | +0.51% |
| Week 2 | $7.14 | $9.29 | $12.11 | +1.02% |
| Week 3 | $6.76 | $9.34 | $12.91 | +1.54% |
| Week 4 | $6.46 | $9.39 | $13.65 | +2.06% |
| Week 5 | $6.21 | $9.44 | $14.33 | +2.58% |
| Week 6 | $6.00 | $9.49 | $14.99 | +3.10% |
| Week 7 | $5.81 | $9.53 | $15.63 | +3.62% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
The company also develops three product candidates, SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), SP-103 (lidocaine topical system) 5.4%, and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), with agreements including Oishi and Itochu to develop lidocaine tape products, Lifecore Biomedical, LLC for SEMDEXA manufacturing and development services, and Tulex Master for SP-104. Scilex Holding Company is based in Palo Alto, California.
Scilex Holding Company (SCLX) is traded with a current price of $9.13 and a market cap of $64.21M, ranking 4451 by size. The price outlook is shaped by a year-by-year forecast that shows periods of neutral timing near the current price and increasingly bullish momentum toward the late 2020s and into the 2030s and beyond.
The forecast highlights a path of rising averages, with 2026 showing an avg near the current level and higher upside potential in later years, including 2030 and beyond. The long-run view points to substantial upside by 2040 and 2050, consistent with bullish sentiment in the later forecast years.
A major floor 53.2% below — a decisive break under it would weaken the trend.
The nearest floor, 53.2% below — buyers have tended to step in here.
The nearest ceiling, 7.9% above — a clean break opens room to run.
A major ceiling 35.7% above — clearing it would confirm fresh momentum.
Key SCLX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SCLX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $9.16 | Buy | $9.08 | Buy |
| MA 10 | $8.42 | Buy | $8.61 | Buy |
| MA 20 | $7.87 | Buy | $8.13 | Buy |
| MA 50 | $7.73 | Buy | $7.81 | Buy |
| MA 100 | $7.62 | Buy | $8.45 | Buy |
| MA 200 | $11.59 | Sell | $10.58 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 62.33 | Neutral |
| Stoch RSI (14) | 74.24 | Neutral |
| CCI (20) | 133.83 | Buy |
| Williams %R (14) | -14.66 | Info |
| MACD (12,26,9) | 0.24 | Buy |
| ROC (12) | 37.79 | Buy |
| Bollinger %B (20,2) | 0.90 | Neutral |
| Stochastic %K (14) | 85.34 | Sell |
| TRIX (15) | 0.47 | Buy |
| Awesome (5,34) | 1.56 | Buy |
| Ultimate (7,14,28) | 70.08 | Sell |
| Momentum (10) | 2.39 | Buy |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 9.76 | Sell |
| ADX (14) | 13.90 | Neutral |
| ATR (14) | 0.47 | Info |
The near-term technical picture is bullish, with RSI14 at 70. The 50-day simple moving average is $5.61, while the 200-day simple moving average is $7.56. The 30-day price range runs from a low of $5.58 to a high of $14.95, illustrating a broad trading band in the near term.
Support is noted at $3.99 and resistance at $9.93, suggesting a defined path for price action within the 30-day window.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.69 | $9.20 | $14.07 | 0% | Neutral | |
| $7.38 | $10.17 | $15.16 | +11% | Neutral | |
| $8.86 | $12.98 | $20.62 | +41% | Bullish | |
| $13.40 | $20.68 | $34.47 | +125% | Bullish | |
| $13.68 | $22.12 | $38.40 | +140% | Bullish | |
| $13.88 | $23.47 | $42.18 | +155% | Bullish | |
| $13.82 | $24.38 | $45.16 | +165% | Bullish | |
| $11.77 | $21.62 | $41.16 | +135% | Bullish | |
| $14.62 | $27.93 | $54.53 | +204% | Bullish | |
| $17.33 | $34.41 | $68.73 | +274% | Bullish | |
| $21.07 | $46.82 | $102.78 | +409% | Bullish | |
| $60.13 | $133.63 | $307.34 | +13.5x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.69 | $9.20 | $11.88 | +0.00% |
| August 2026 | $8.39 | $10.17 | $12.84 | +10.54% |
| September 2026 | $8.00 | $9.83 | $12.67 | -3.34% |
| October 2026 | $8.04 | $10.01 | $13.12 | +1.79% |
| November 2026 | $8.53 | $10.72 | $14.26 | +7.16% |
| December 2026 | $8.23 | $10.44 | $14.07 | -2.64% |
Click any year to see its month-by-month SCLX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Scilex Holding Company's 2026 outlook centres on $9.20, within a $3.69 to $14.07 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, SCLX could reach as high as $15.16, with a base case around $10.17 and support toward $7.38 — roughly +11% from $9.20. Price action looks broadly range-bound.
Expect SCLX to range from $8.86 to $20.62 through 2028. The $12.98 average target implies a +41% move from current prices. That is up +28% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The SCLX price prediction for 2029 points to an average of $20.68 (low $13.40, high $34.47) — a potential gain of +125% on today's $9.20. Momentum favours further upside here.
In 2030, SCLX is projected to trade between $13.68 and $38.40, averaging $22.12 — a potential gain of +140% from today's $9.20. That is up +7% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Scilex Holding Company's 2031 outlook centres on $23.47, within a $13.88 to $42.18 range. That is up +6% on the projected 2030 average. That marks a +155% change versus current levels. Momentum favours further upside here.
By 2032, SCLX could reach as high as $45.16, with a base case around $24.38 and support toward $13.82 — roughly +165% from $9.20. Buyers look set to stay in control over this stretch.
Expect SCLX to range from $11.77 to $41.16 through 2033. The $21.62 average target implies a +135% move from current prices. That is -11% versus the projected 2032 average. Momentum favours further upside here.
The SCLX price prediction for 2034 points to an average of $27.93 (low $14.62, high $54.53) — a potential gain of +204% on today's $9.20. Buyers look set to stay in control over this stretch.
In 2035, SCLX is projected to trade between $17.33 and $68.73, averaging $34.41 — a potential gain of +274% from today's $9.20. That is up +23% on the projected 2034 average. Momentum favours further upside here.
Scilex Holding Company's 2040 outlook centres on $46.82, within a $21.07 to $102.78 range. That is up +36% on the projected 2035 average. That marks a +409% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, SCLX could reach as high as $307.34, with a base case around $133.63 and support toward $60.13 — roughly +13.5x from $9.20. Momentum favours further upside here.
Investing $1,000 in SCLX today (≈ 108.695652 SCLX) could be worth
$14,524.72
+$13,524.72 (+1352%) by 2050 · US Dollar
Based on the average projected SCLX price of $133.63 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SCLXwould be worth at today's price.
$1,000 invested in SCLX on Jul 10, 2025 (≈ 154.08321 SCLX) would be worth
$1,417.57
+$417.57 (+41.8%) today · 1.42× · US Dollar
Based on a SCLX entry price of $6.49 vs. today's $9.2.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $7.81 | $1,177.98 | +17.8% |
| 1 month ago | $8.8 | $1,045.45 | +4.5% |
| 3 months ago | $6.8 | $1,352.94 | +35.3% |
| 6 months ago | $13.4 | $686.57 | -31.3% |
| 1 year ago | $6.49 | $1,417.57 | +41.8% |
| All time (5.0y) ago | $347.55 | $26.47 | -97.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SCLX forecast.
Our base-case forecast reaches $18.00 around 2029.
Implied market cap at $18.00: $126.59M
The multi-year forecast shows a rising price trajectory with mixed near-term signals and stronger long-run upside. In 2026, the min price is $3.69, the avg is $9.13, and the max is $13.84, with ROI 0 and sentiment Neutral. In 2027, the min is $7.23, the avg is $9.97, the max is $14.86, with ROI 9.2 and sentiment Neutral.
From 2028 onward, the outlook turns bullish, with 2028 at min $8.61, avg $12.61, max $20.03 and ROI 38.1; 2029 at min $12.89, avg $19.90, max $33.18 and ROI 117.9; 2030 at min $13.19, avg $21.34, max $37.05 and ROI 133.8. The forecast continues to show gains through 2031–2032 (avg $22.55, $23.23) and beyond, with 2034–2035 showing notable expansion (avg $26.45, $32.15) and higher ROIs, followed by sustained bullish momentum into 2040 (avg $43.94, max $96.46; ROI 381.2) and 2050 (avg $122.85, max $282.57; ROI 1245.6).
Overall, sentiment remains BULLISH in the later years, reflecting a broad upward price trajectory. These figures are estimates and not guarantees, and actual results may vary.
Tap a question to reveal the answer.
2030 avg $21.34, min $13.19, max $37.05; ROI 133.8%; sentiment BULLISH.
Forecasts show upside with 2030 avg $21.34; 2040 avg $43.94; 2050 avg $122.85; ROIs up to 133.8%, 381.2%, and 1245.6% respectively, though these are estimates and not guarantees.
Yes, the 2050 max is $282.57 and the 2040 max is $96.46, so $100 is within the projected max by 2050.
Current price $9.13 and market cap $64.21M.
RSI14 is 70; SMA50 is $5.61; SMA200 is $7.56. The 30-day range is $5.58 to $14.95, with support at $3.99 and resistance at $9.93.
Scilex Holding Company Community Discussion
0Share your Scilex Holding Company price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.